Core Insights - Strata Critical Medical, Inc. has completed the acquisition of Keystone Perfusion Services LLC, enhancing its position as a full-service organ transplant service provider [1][2][5] - The acquisition is expected to generate approximately $65 million in revenue and $13 million in Adjusted EBITDA for Keystone in 2025, with revenue projected to grow over 50% compared to 2024 [5][7] - The transaction was valued at $124 million, representing an approximate 9x multiple of Keystone's estimated Adjusted EBITDA for 2025 [4][5][13] Company Overview - Strata Critical Medical provides critical logistics solutions and specialized medical services across the U.S., focusing on expanding its service portfolio through acquisitions and organic growth [9] - Keystone Perfusion Services is a leading provider of normothermic regional perfusion and organ recovery services, supporting organ procurement organizations and transplant centers [12] Strategic Implications - The acquisition allows Strata to offer additional critical services directly to transplant customers, which were previously arranged through third parties [3][5] - Keystone's non-transplant services represent a new market opportunity for Strata, with significant growth potential in fragmented medical sectors [3][5] Financial Outlook - The financial guidance for 2025 has been updated to reflect the impact of the Keystone acquisition, with expectations for revenue between $180 million to $190 million and Adjusted EBITDA between $13 million to $14 million [14] - The company plans to provide further guidance for 2026, including the impact of the Keystone acquisition, during an investor day scheduled for November 17, 2025 [7]